Navigation Links
Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Date:11/5/2007

BRISBANE, Australia, Nov. 5 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced additional data from the Phase 2 liver cancer study of PI-88 completed earlier this year. This data was presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA(1).

As the Phase 2 trial's study period covered 48 weeks from curative surgery, the data analysis described in this presentation was performed to evaluate the treatment's impact when patients with a low risk of experiencing a liver cancer recurrence within twelve months are removed from the analysis population. Patients were removed from the patient population if, based on published prognostic factors, they were considered likely to complete the 12 months of the study without recurrence.

The resultant analysis of those patients who had a high risk of recurrence in the 12-month period shows that PI-88 at least doubled the time to disease recurrence calculated at the 60th percentile (p=0.0107) (control (n=33): 24 weeks versus 160mg PI-88 (n=36): 48 weeks). This compares to a 76% improvement at the 70th percentile (p=0.0867) if all patients are included, as reported earlier this year.

Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs, commented: "We know that around 50% of untreated patients are likely to experience disease recurrence within 12-15 months after they have had curative liver cancer resection. Given our Phase 2 study only assessed the recurrence of disease up to 12 months after surgery; this implies that approximately half of the study population were unable to provide information about the efficacy of the drug. When you remove from the analysis patients unlikely to recur in the study time frame, the treatment effect of PI-88 as measured in the Phase 2 study is more clearly demonstrated."

Dr. Garner further commented: "These data further expand our confidence that ou
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ING, Nov. 30 /PRNewswire-Asia-FirstCall/ -- Lotus ..."Lotus" or the "Company") a growing developer and,...al seller of pharmaceutical,products in the People...its,Over-the-Counter Drug division ("OTC Division"...more than five hundred drug stores in Beijing as o...
(Date:11/30/2009)...TER, N.J., Nov. 30 Sanof...xclusive licensing agreement with Intelliject, Inc...ergency treatment of allergic reactions (anaphylax... are pleased to have this opportunity to offer thi...eople who are at risk of this life-threatening all...
(Date:11/30/2009)...November 30 , -...the European Union in,the Last 10 Years , ...nnounced today that the,European Commission has gr...darone - 400mg Tablets) in all 27 European member ...ion positive opinion issued on September 25, 2009,...
Breaking Medicine Technology:Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores 2Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores 3Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 2Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 3Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 4Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 5Cardin Calls on NIH to Utilize Small Businesses for Extramural Research Projects 49679 1Cardin Calls on NIH to Utilize Small Businesses for Extramural Research Projects 49679 2President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 1President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 2President Obama Delivers Historic Victory for Americas Kids and Health over Tobacco 49675 3Social Activity Keeps Elders Young Agile 49673 1Social Activity Keeps Elders Young Agile 49673 2Social Activity Keeps Elders Young Agile 49673 3
... ANNANDALE, Va., May 4 EPSScentral LLC today anno...embling, communicating, and implementing mitigatio...tion of the Influenza A crisis. According to the ...ic is imminent and that the time to finalize... mi...//www.newscom.com/cgi-bin/prnh/20080701/DC26612LOG...
... Patients Experience Significant Improvement in Oc...RENCEVILLE, N.J., May 4 Aton Pharma, Inc. announc...-center patient registry study of its Lacrisert(R)...ing the 2009 Annual Meeting of the Association for...3-7, Ft. Lauderdale, FL, and later in the month at...
Other Medicine Technology:EPSScentral Responds to Pandemic Alert 2ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 2ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 3ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 4ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert; 5
(Date:11/30/2009)... , SILVER SPRING, Md., Nov. 30 /PRNewswir... consumers a bronzed body year-round, but the ultr...rious health risks. ,, (Logo: http://www.news...though some people think that a tan gives them a ,...says Sharon Miller, M.S.E.E., a Food and Drug Admi...
(Date:11/30/2009)..., CHICAGO, Nov. 30 Physicians a...ported today on results of a study demonstrating t... angiography (cCTA) by Rcadia,s COR Analyzer Syste...rtery stenosis in hospital emergency department (E...utomated system to enhance the use of cCTA has pot...
(Date:11/30/2009)...niversity of Navarra Hospital has launched a serie...cy of an immunotherapy treatment. This approach in...oduced from healthy and tumour cells from the pati...tomas, one of the most aggressive and frequent mal... participating patients combined with the standard...
(Date:11/30/2009)... Peter J. Rappa, MD, explores th...dy in his new book "Healing Heart to Soul: On...ife" (Brown Books 2009). , ...periencing and refusing to let go of negative emot... can weigh heavy on our shoulders. Oftentimes, thi...
(Date:11/30/2009)... , NEW YORK, Nov. 30 Repo...report is available in its catalogue: ,, Gene ...unities ,, http://www.reportlinker.com/p01642...ortunities.html ,, Gene therapy promises to b... Although no significant achievements for curing d...
Breaking Medicine News(10 mins):Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health 2Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 2Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 3Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 4Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 5
...ge for nicotine, rat study suggests , , MO...peptide receptor in the brain may be one way to qu...dy suggests. , Hypocretin-1, or Orexin A, a short ...he addictive chemical in tobacco, according to res...
...dicines for conditions that haven,t been studied t...ews) -- It,s called "off-label" prescribing, and i...rug to treat a disease or condition that,s differe...ittle evidence that using a drug for an unapproved...
... to treat anemia in patients with cancer are assoc...lood clots, at a similar rate as other treatments ... at the University of Rochester Medical Center. ,...leading causes of illness and death in people with...
... 24, 2008 A new study finds that youth population...dequate healthcare, and thus may fail to benefit f...Pediatric Blood & Cancer , finds that the patients... abnormally shaped red blood cells, affects close ...
...d by the termite Termes panamensis (Snyder), whi...rded, is sufficient to kill a would-be nest invade...l fellows at the Smithsonian Tropical Research Ins... Panama, established by a donation from the Frank ...
...erdam, The Netherlands and Sun City, AZ, USA -- A ...nal of Alzheimer,s Disease (Volume 15:3) suggests...ment Scale Cognitive (ADAS-Cog) may vary and poss...that contribute to variances seen in this assessme...
Other Medicine News:Health News:Molecular Switch in Brain May End Smokers' Cravings 2Health News:Study Calls for Greater Scrutiny of 'Off-Label' Drug Use 2Health News:Study Calls for Greater Scrutiny of 'Off-Label' Drug Use 3Health News:Study Calls for Greater Scrutiny of 'Off-Label' Drug Use 4Health News:Transfusions increase clot risk in hospitalized cancer patients 2Health News:Children with sickle cell disease receiving inadequate care 2Health News:Panamanian termite goes ballistic: Fastest mandible strike in the world 2Health News:Study suggests reliability of cognitive assessment tool varies widely 2
...e OrthoPilot, physicians now have a tool for the p...,The only platform you need for all orthopedic in...tem requiring little space. Continuous software up... OrthoPilot a strong and trustworthy partner. At t...
Optifield EP-900 Series
AP-125 Automatic Perimeter
...EXCLUDER AAA Endoprosthesis is an innovative devic...tion for patients with abdominal aortic aneurysms ...ated graft with an outer self-expanding Nitinol su... and material durability. The function of the endo...
Medicine Products: